In Silico Exploration of Novel Tubulin Inhibitors: A Combination of Docking and Molecular Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening

Farzin Hadizadeh,1,2 Razieh Ghodsi,1,2 Salimeh Mirzaei,3 and Amirhossein Sahebkar1,2,4,5

1Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3Department of Medicinal Chemistry, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
4Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Salimeh Mirzaei; mirzaeis@hums.ac.ir

Received 11 June 2021; Revised 5 September 2021; Accepted 17 December 2021; Published 15 January 2022

Academic Editor: David Diller

Copyright © 2022 Farzin Hadizadeh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Microtubules play a critical role in mitosis and cell division and are regarded as an excellent target for anticancer therapy. Although microtubule-targeting agents have been widely used in the clinical treatment of different human cancers, their clinical application in cancer therapy is limited by both intrinsic and acquired drug resistance and adverse toxicities. In a previous work, we synthesized compound 9IV-c, ((E)-2-(3,4-dimethoxystyryl)-6,7,8-trimethoxy-N-(3,4,5-trimethoxyphenyl)quinoline-4-amine) that showed potent activity against multiple human tumor cell lines, by targeting spindle formation and/or the microtubule network. Accordingly, in this study, to identify potent tubulin inhibitors, at first, molecular docking and molecular dynamics studies of compound 9IV-c were performed into the colchicine binding site of tubulin; then, a pharmacophore model of the 9IV-c-tubulin complex was generated. The pharmacophore model was then validated by Güner–Henry (GH) scoring methods and receiver operating characteristic (ROC) analysis. The IBScreen database was searched by using this pharmacophore model as a screening query. Finally, five retrieved compounds were selected for molecular docking studies. These efforts identified two compounds (b and c) as potent tubulin inhibitors. Investigation of pharmacokinetic properties of these compounds (b and c) and compound 9IV-c displayed that ligand b has better drug characteristics compared to the other two ligands.

1. Introduction

Microtubules made of α- and β-tubulin heterodimers in eukaryotic cells and are vital components of the cytoskeleton which are involved in numerous cellular processes such as cell signaling, cell motility, and intracellular vesicle transport [1–3].

Microtubules form highly dynamics mitotic spindles, which are vital for the suitable orientation and segregation of chromosomes; disruption of this equilibrium will lead to cell cycle arrest or cell apoptosis [4–6].

Microtubule-targeting agents (MTAs) are divided into two classes including microtubule stabilizers such as taxanes which bind to the paclitaxel binding site that stabilize the
tubulin polymer form and microtubule-destabilizing agents like vinca alkaloids and colchicine which bind to the colchicine and vinblastine binding site which inhibit tubulin polymerization into microtubules [6–8]. Despite the progress in the administration of microtubule targeting agents for the treatment of patients with cancer, currently, there are no FDA-approved tubulin inhibitors targeting the colchicine binding site [9]. This has encouraged medicinal chemists to design and discover the novel antimitic agents that bind to the colchicine binding site for cancer therapy [10–16].

Pharmacophore is defined as an ensemble of steric and electronic features that is necessary to reach the optimal interactions of a ligand with the catalytic site of a protein and very well accepted in the medicinal chemistry laboratory [17–19].

In a previous work, we synthesized a new series of styrylquinolines that among them, compound 9IV-c, ((E)-2-(3,4-dimethoxystyryl)-6,7,8-trimethoxy-N-(3,4,5-trimethoxyphenyl)quinoline-4-amine) (Figure 1) exhibited a potent activity against multiple human tumor cell lines, by targeting spindle formation and/or the microtubule network [4]. In this work, to identify potent tubulin inhibitors, at first, to explain the possible binding mode of compound 9IV-c and to evaluate the validity of docking results, molecular docking and molecular dynamics studies of this compound, respectively, were performed into the colchicine binding site of tubulin; then, a pharmacophore model of 9IV-c-tubulin complex was generated. It was then used as a screening query to obtain potent small molecules from an IBScreen database. Five hits were obtained in this step for a match to the pharmacophore model which was subjected to molecular docking studies. Finally, two compounds b and c with the lowest binding-free energies were selected as potent tubulin inhibitors. The pharmacokinetic properties of these compounds were studied using SwissADME software.

2. Results and Discussion

2.1. Molecular Modeling. To study the manner of interactions between compound 9IV-c and tubulin, this compound was docked into the colchicine binding site of tubulin (PDB ID: 4O2B) via MOE 2015.10 [4]. The studies exhibited that the compound 9IV-c docked well in the colchicine-binding site with a binding free energy of -9.759 kcal/mol (Figures 2(a) and 2(b)). The hydrogen-bonding interactions (purple dashed line in Figure 2(a)) were seen between the methoxy group of A-ring of compound 9IV-c with residue Asn 258β and also nitrogen atom of quinoline ring with Ala 180α and the methoxy group of D-ring with Asn 249β. Further, the hydrophobic interactions between quinolines with different amino acids such as Gln11α, Asn258β, Thr352β, Lys254β, Ser178α, Ala250β, Asn350β, Val351β, Lys352β, and Leu255β have been observed (Figure 2(b)).

Figure 2(c) shows the binding mode of compound 9IV-c with colchicine, the standard tubulin inhibitor, at the active site of colchicine in tubulin. The binding mode observed for 9IV-c was very similar to that for colchicine in the cocrystallized tubulin structure. The trimethoxyphenyl group of 9IV-c, which is an essential pharmacophore for tubulin inhibitors, was placed in the same position as the corresponding moiety of colchicine.

2.2. Molecular Dynamics Simulation. Molecular dynamics (MD) simulation studies were performed to obtain a more exact ligand-receptor model in a state near to the natural situations [7]. For this goal, the docked structure of compound 9IV-c was used as the initial structure for 100 ns MD simulations. After accomplishment of the simulation process, the complex was examined for root mean square deviation (RMSD), radius of gyration (Rg), and hydrogen bonds [20].

RMSD determines the stability of the constructions. The RMSD of backbone (Ca, C, and N) of apo-form and ligand-bond protein was shown in Figure 3. The average RMSD value of ligand-bond protein was 1.536 ± 0.212 Å, whereas the apo-form was with an average RMSD value of 1.776 ± 0.292 Å. In RMSD of apo-form, the change was larger than ligand-bond protein. It seemed that binding of the ligand with protein decreased the conformation flexibility of protein and the complex reached stability during the simulation.

Rg (radius of gyration) is an indicator of the protein structure density and measures the distance of region’s parts from its center of gravity. As shown in Figure 4. Rg values of the apo-form and ligand-bond protein were 30.24 ± 0.125 and 30.089 ± 0.0.091 Å (mean ± SD), respectively. This confirms the stabilization and nonsignificant conformational changes in the structure of the ligand-bound protein [20].

Hydrogen bonds have a key role in the stability of the ligand-protein complex. This stability of the hydrogen-bond network was because of the presence of the ligand in the protein binding site. The findings revealed that ligand made one to two hydrogen bonds with protein (Figure 5). These hydrogen bonds increased binding affinity of the ligand with protein. The mean of intramolecular hydrogen bonds of the protein was 196.96 ± 11.96 (Figure 6.). These hydrogen bonds stabilized the secondary structure of protein.

The 2D representation of the interaction between compound 9IV-c with the colchicine binding site after 100 ns simulation by LigPlot has been depicted in Figure 7.

2.3. Pharmacophore Generation. Molecular docking and molecular dynamics studies showed that the compound
**9IV-c** binds well to the colchicine binding site of tubulin and the interaction of this ligand with the tubulin, stabilizes the protein structure. Therefore, using MOE software, a pharmacophore model was generated based on the docked structure of compound **9IV-c** in the colchicine binding site, to acquire the chemical features on the inhibitor binding of the tubulin [18, 21]. The generated model included four features (Figures 8(a) and 8(b)): two hydrogen bond donor feature (F1 & F2: Don) which are generated by nitrogen atom of quinoline ring and the nitrogen atom of aniline ring, one aromatic feature (F3: Aro), and one hydrophobic feature (F4: Hyd) which are produced by a double bond of styryl section.

**2.4. Validation of the Pharmacophore Model.** To validate the reliability of the pharmacophore model constructed in this study, Güner–Henry (GH) scoring methods and receiver operating characteristic (ROC) analysis were used.

**2.4.1. GH Scoring Method.** The GH score method was used to evaluate the discriminative ability of the pharmacophore model in distinguishing active compounds from the inactive compounds from a testing set database including 20 known tubulin inhibitors and 600 inactive molecules [3, 12, 22–25]. The GH analysis by computing parameters such as total hits (Ht), active hits (Ha), enrichment factor (E), and goodness...
of hit score (GH) were performed (Table 1). GH score was observed to be 0.69 for the model, representing that the pharmacophore model has a good ability to discriminate active compounds from inactive ones.

2.4.2. ROC Studies. The pharmacophore model was used to receiver operating curve (ROC) analysis to assess its ability to suitably classify a list of compounds as active or inactive [26]. The ROC curve obtained for the validation showed an AUC value of 0.84 (Figure 9), indicating that the model differentiated the active compounds from the inactive ones efficiently \((p < 0.001)\). The sensitivity and specificity of the model were 80\% and 98.66\%, respectively.

2.5. Virtual Screening and Identifying Potential Inhibitors. The IBScreen database (containing 158210 compounds) was searched by using the 2D chemical structure of compound 91V-c (Figure 1.) as a query to find compounds with similar structures to this compound [27]. At this step, a total of 1257 compounds were obtained based on the most similarity to compound 91V-c; this set was then screened based on the created pharmacophore model. As a result, five ligands (a–e) were confirmed to fit with the pharmacophore model (Table 2). These compounds were then docked into the colchicine binding site, and two ligands b and c were selected with the lowest binding-free energies and the best modes of interactions with the colchicine binding site.

Interactions of compounds b and c with tubulin protein are shown in Figures 10 and 11. It can be observed that compounds b and c have better free binding energies in comparison with compound 91V-c \((-10.498 \text{ and } -10.083 \text{ kcal/mol for b and c, respectively, and } -9.759 \text{ for 91V-c})\). This subject suggests that these compounds (b and c) may interact with higher potencies than compound 91V-c.

As seen in Figure 11(a) and 11(b), molecular docking analysis of compound b displayed two hydrogen bond interactions between acidic substituents with residues of Lys 352β and the nitrogen atom of quinoline ring with residues of Thr 179α and a cation-π interaction between residue Leu 248β and one of the phenyl rings (Figure 11(a)). The sulfonami group of compound c formed two hydrogen bond interactions with residues Lys254β and Asn249β (Figure 11(b)). These compounds formed hydrophobic interactions with residues Leu255β, Lys248β, Asn258β, Ser178α and Asn101α, and Gln11α.

2.6. Pharmacokinetic Property Prediction. In this study, by using the SwissADME software, drug development involves the process of adsorption, distribution, metabolism, and excretion (ADME), for three ligands b, c, and 91V-c was performed [28]. The test results can be seen in Table 3.

The results of the tests in the gastrointestinal absorption parameter showed that ligand b (with the high result) are suitable for oral use. It was also found that ligands c and 91V-c with low results are not well used orally, but may be used as an injection.

The results of yes, in the cytochrome inhibitor parameter, will indicate that ligand can act as an inhibitor in the process of cytochrome metabolism, while no results will show that the ligand cannot act as an inhibitor in the process of cytochrome metabolism [29]. The test results show that three ligands were cytochrome inhibitors.

The higher bioavailability of the compound indicates that it can be better used orally [29]. Based on the results obtained from this parameter (Table 3), all three ligands have good bioavailability values, and among these, ligand b, which exhibited better results in docking studies, has better bioavailability.
Figure 6: Number of intramolecular hydrogen bonds of protein in time scale.

Figure 7: A diagrammatic representation of interactions between ligand 9IV-c at the active site of tubulin after 100 ns molecular dynamics simulation. The green dotted lines represent hydrogen bond interaction, and red arcs with radiating spokes represent the amino acids showing hydrophobic interaction with protein. Carbon, nitrogen, and oxygen atoms have been shown in black, blue, and red, respectively. The violet lines represent the ligand bond.
3. Conclusion

In this research, molecular docking and molecular dynamics studies of compound 9IV-c (a potent inhibitor of tubulin polymerization found in previous work) were performed into the colchicine binding site of tubulin. The studies exhibited modes of interaction of compound 9IV-c with tubulin including the formation of hydrogen bonds and hydrophobic interactions and also characterized the stability of this compound during a 100 ns simulation run. Then, a pharmacophore model of the 9IV-c-tubulin complex was generated. The created model included two hydrogen bond donor features (F1 & F2: Don), one aromatic feature (F3: Aro), and one hydrophobic feature (F4: Hyd). The pharmacophore model was then validated by Güner–Henry (GH) scoring methods and receiver operating characteristic (ROC) analysis. GH score was observed to be 0.69 for the model, representing that the pharmacophore model has a good ability to discriminate active compounds from inactive ones.

The IBScreen database (containing 158210 compounds) was searched by using the 2D chemical structure of compound 9IV-c as a query to find compounds with similar structures to this compound and was then screened based on the generated pharmacophore model, and five ligands (a–e) verified to fit with the pharmacophore model. These compounds were then docked into the colchicine binding site, and two ligands b and c were selected with the lowest binding free energies and the best modes of interactions with the colchicine binding site. These ligands (ligands b and c)
| Compounds | IBScreen ID     | Structures                                      | Binding energies (kcal/mol) |
|-----------|----------------|-------------------------------------------------|----------------------------|
| a         | STOCK4S-95238  | ![Structure a](image1.png)                      | -7.842                     |
| b         | STOCK1S-15990  | ![Structure b](image2.png)                      | -10.498                    |
| c         | STOCK6S-14477  | ![Structure c](image3.png)                      | -10.083                    |
| d         | STOCK3S-48351  | ![Structure d](image4.png)                      | -8.014                     |
| e         | STOCKIS-43560  | ![Structure e](image5.png)                      | -8.350                     |
and compound 9IV-c were tested for ADMET parameters and pharmacokinetic properties. The results displayed that ligand b has better drug characteristics compared to the other two ligands.

4. Materials and Methods

4.1. Molecular Modeling. The 2D structure of the compound was organized in ChemDraw Ultra 8.0 software, and the 3D structure was obtained using Hyperchem 7 software through molecular mechanic force filed preoptimization and then by AM1 semiempirical calculation. The X-ray crystal structure of tubulin (PDB ID: 4O2B) was downloaded from the PDB (Protein Data Bank). Further changes (addition of polar hydrogen or deletion of water molecules) were done by MOE software. Compounds were docked into the binding site of tubulin using MOE software. The top-score docking poses were selected for final ligand-target interaction analysis using the LigX module in MOE Software [30].

4.2. Molecular Dynamics Simulation. Molecular dynamics (MD) simulation studies were performed to find the interaction between protein and ligand in atomic details in the real natural situation (aqueous solution at $T=37^\circ C$, $P=1$ atm). Calculations were performed using NAMD 2.12 program (http://www.ks.uiuc.edu/Research/namd) with the CHARMM27 force field. To analyze results Visual Molecular Dynamics (VMD) (http://www.ks.uiuc.edu/Research/vmd) was used. The force field parameters of ligand 9IV-c were provided by SwissParam (http://swissparam.chr). The whole systems were immersed in the center of a TIP3 water box with dimensions 97.117 Å × 113.789 Å × 97.287 Å, using the VMD program. The systems were neutralized by adding sodium and chloride ions. The Particle-Mesh Ewald (PME) algorithm with a grid spacing of 1 Å and periodic boundary conditions was applied. A cut-off of 15 (Å) was used for the short-range Lennard-Jones interactions. Finally, MD simulations were performed with a time step of 2 fs for 100 ns. The trajectory of the system was stored at every 1 ps and analyzed by VMD analyzer tools. The system was complex and required significant computational. A system with a processor: AMD Ryzen Threadripper 1950X 16- Core, 3.40 GHz and installed memory (RAM) 32.0 GB, was used in this study [31].

4.3. Pharmacophore Model Generation. The docked structure of compound 9IV-c in the colchicine binding site of tubulin was used for pharmacophore model generation. To create the most descriptive features of the colchicine binding site of tubulin, the Pharmacophore Query Editor of MOE was employed. These features are indicated as spheres that characterize the important interaction points of the ligand with the active site of tubulin [18, 29].

4.4. Validation of the Pharmacophore Model

4.4.1. GH Scoring Method. The Güner–Henry (GH) scoring method quantifies the importance of the generated model by retrieving the active compounds from a database containing known active and inactive molecules [23, 32]. To evaluate the discriminating ability of the generated pharmacophore model a testing set database including 20 known tubulin inhibitors with experimental activity and 600 inactive molecules was searched by the pharmacophore model as a 3D structural search query. The retrieved compounds are selected based on according to their RMSD value. Lower RMSD values show better quality of the matching of the molecule to the pharmacophore model. The GH score was calculated using the following formulae: [24].

$$\text{EF} = \frac{H_a/H_i}{A/D},$$

$$\text{GH} = \frac{H_a(3A + H_i)}{4H_iA} \left( 1 - \frac{H_i - H_a}{D - A} \right).$$

Here, $D$ is the number of compounds in the database, $A$ is the number of active compounds, $H_i$ is the number of hits retrieved, $H_a$ is the number of actives in hit list, EF is the enrichment factor, and GH is the Güner–Henry score. The GH score ranging from 0.6 to 1 would indicate an optimal pharmacophore model.

4.4.2. Analysis Using ROC. To evaluate the pharmacophore model, receiver operating characteristic (ROC) curve analysis was also performed using MedCalc statistical software (http://www.medcalc.org). In ROC analysis, the ability of the obtained pharmacophore model was indicated with the area under the curve (AUC) to distinguish a list of compounds as active or inactive compounds in terms of two parameters, sensitivity and specificity.

4.5. Screening of the Database Based on Pharmacophore Models. The IBScreen database containing 158210 compounds was used. At first, using ChemFinder software the 2D chemical structure (SMILES file format) of compound 9IV-c (Figure 1.) was used as a query in the IBScreen database to find compounds with similar structures to this compound. The applied filter gave a total of...
1257 compounds. The result structures were downloaded in a SDF format. Database preparation in MOE software was performed based on default settings. Then, the generated pharmacophore model (3D structure) was used as a screening query by MOE to find compounds with similar binding features of compound 9IV-c as tubulin inhibitor. Compounds retrieved from pharmacophore filtering were then docked into the colchicine binding site of tubulin, and the ligands with the lowest docking energies were chosen.

### Table 3: The pharmacokinetic properties prediction by SwissADME software.

| Ligand | GI absorption | CYP1A2 | CYP2C19 | CYP2C9 | CYP2D6 | CYP3A4 | Bioavailability |
|--------|---------------|--------|---------|--------|--------|--------|----------------|
| b      | High          | Yes    | Yes     | Yes    | Yes    | No     | 0.85           |
| c      | Low           | Yes    | Yes     | No     | Yes    | Yes    | 0.55           |
| 9IV-c  | Low           | No     | Yes     | No     | No     | No     | 0.55           |

1: CYP1A2; 2: CYP2C19; 3: CYP2C9; 4: CYP2D6; 5: CYP3A4.
Data Availability

Data are available upon a reasonable request from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We are grateful to Hormozgan University of Medical Sciences for financial support of this research. We should also thank Professor Mohammad Reza Saberi, the head of bioinformatics lab of department of medicinal chemistry in Mashhad University of medical sciences, for letting us to perform molecular dynamics simulations.

References

[1] L. Li, S. Jiang, X. Li, Y. Liu, J. Su, and J. Chen, “Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site,” European Journal of Medicinal Chemistry, vol. 151, pp. 482–494, 2018.

[2] Q. Lai, Y. Wang, R. Wang et al., “Design, synthesis and biological evaluation of a novel tubulin inhibitor targeting the colchicine binding site,” European Journal of Medicinal Chemistry, vol. 156, pp. 162–179, 2018.

[3] Y. Sun, B. Pandit, S. N. Chettiar et al., “Design, synthesis and biological studies of novel tubulin inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 15, pp. 4465–4468, 2013.

[4] S. Mirzaei, F. Eisvand, F. Hadizadeh, F. Mosaffa, A. Ghasemi, and R. Ghodsi, “Design, synthesis and biological evaluation of novel 5,6,7-trimethoxy-N-aryl-2-styrylquinolin-4-amines as potential anticancer agents and tubulin polymerization inhibitors,” Bioorganic Chemistry, vol. 98, article 103711, 2020.

[5] Y. Zhou, W. Yan, D. Cao et al., “Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents,” European Journal of Medicinal Chemistry, vol. 138, pp. 1114–1125, 2017.

[6] T. Beckers, T. Reissmann, M. Schmidt et al., “2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors,” Cancer Research, vol. 62, no. 11, pp. 3113–3119, 2002.

[7] S. Mirzaei, F. Hadizadeh, F. Eisvand, F. Mosaffa, and R. Ghodsi, “Synthesis, structure-activity relationship and molecular docking studies of novel quinoline-chalcone hybrids as potential anticancer agents and tubulin inhibitors,” Journal of Molecular Structure, vol. 1202, article 127310, 2020.

[8] K. Nakagawa-Goto, Y. Taniguchi, Y. Watanabe et al., “Triethylated chromones with substituted naphthalenes as tubulin inhibitors,” Bioorganic & Medicinal Chemistry, vol. 24, no. 22, pp. 6048–6057, 2016.

[9] S. Mirzaei, F. Eisvand, F. Hadizadeh, F. Mosaffa, and R. Ghodsi, “Design, synthesis, and biological evaluation of novel 5, 6, 7-trimethoxy quinolines as potential anticancer agents and tubulin polymerization inhibitors,” Iranian Journal of Basic Medical Sciences, vol. 23, no. 12, pp. 1527–1537, 2020.

[10] S. Mirzaei, M. Qayumov, F. Gangi, J. Behravan, and R. Ghodsi, “Synthesis and biological evaluation of oxazinonaphthalene-3-one derivatives as potential anticancer agents and tubulin inhibitors,” Iranian Journal of Basic Medical Sciences, vol. 23, no. 11, pp. 1388–1395, 2020.

[11] F. S. Behbahani, J. Tabeshpour, S. Mirzaei et al., “Synthesis and biological evaluation of novel benzo[c] acridine-diones as potential anticancer agents and tubulin polymerization inhibitors,” Archiv der Pharmazie, vol. 352, no. 6, article 1800307, 2019.

[12] S. D. Guggilapu, L. Guntuku, T. S. Reddy et al., “Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors,” European Journal of Medicinal Chemistry, vol. 138, pp. 83–95, 2017.

[13] M. P. Tantak, L. Klingler, V. Arun, A. Kumar, R. Sadana, and D. Kumar, “Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors,” European Journal of Medicinal Chemistry, vol. 136, pp. 184–194, 2017.

[14] A. Kumar, M. Kumar, S. Sharma, S. K. Guru, S. Bhushan, and B. A. Shah, “Design and synthesis of a new class of cryptophycins based tubulin inhibitors,” European Journal of Medicinal Chemistry, vol. 93, pp. 55–63, 2015.

[15] T. Naret, J. Bignon, G. Bernadat et al., “A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: design, synthesis, molecular modelling, and biological evaluation,” European Journal of Medicinal Chemistry, vol. 143, pp. 473–490, 2018.

[16] F. Sultana, S. P. Shaik, V. L. Nayak et al., “Design, synthesis and biological evaluation of 2-anilinopyridyl-linked oxindole conjugates as potent tubulin polymerisation inhibitors,” ChemistrySelect, vol. 2, no. 31, pp. 9901–9910, 2017.

[17] H. Sun, “Pharmacophore-based virtual screening,” Current Medicinal Chemistry, vol. 15, no. 10, pp. 1018–1024, 2008.

[18] Y. Zhou, S. Tang, T. Chen, and M. M. Niu, “Structure-based pharmacophore modeling, virtual screening, molecular docking and biological evaluation for identification of potential poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors,” Molecules, vol. 24, no. 23, p. 4258, 2019.

[19] P. Markt, D. Schuster, and T. Langer, “Pharmacophore models for virtual screening,” Virtual Screening: Principles, Challenges, and Practical Guidelines, pp. 115–152, 2011.

[20] H. Arayapour, M. Dehdab, F. Sohrab, and A. Bargahi, “Prediction of new chromosome-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods,” Computational Biology and Chemistry, vol. 71, pp. 89–97, 2017.

[21] Y. S. Tian, N. Kawashita, Y. Ara, K. Okamoto, and T. Takagi, “Pharmacophore modeling and molecular docking studies of potential inhibitors to E6 PDZ from human papilloma virus (HPV),” Bioinformation, vol. 11, no. 8, pp. 401–406, 2015.

[22] G. la Regina, R. Bai, A. Coluccia et al., “New 6- and 7-heterocycl-1 H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors,” European Journal of Medicinal Chemistry, vol. 152, pp. 283–297, 2018.

[23] R.-J. Li, Y. L. Wang, Q. H. Wang, J. Wang, and M. S. Cheng, “In silico design of human IMPDH inhibitors using pharmacophore mapping and molecular docking approaches,” Computational and Mathematical Methods in Medicine, vol. 2015, 11 pages, 2015.

[24] S.-H. Lu, Y. C. Hwang, I. J. Liu et al., “Development of therapeutic antibodies for the treatment of diseases,” Journal of Biomedical Science, vol. 27, no. 1, pp. 1–13, 2020.
[25] S. Zhao, X. Li, W. Peng et al., "Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists," RSC Advances, vol. 11, no. 16, pp. 9403–9409, 2021.

[26] N. Gupta, N. Sitwala, and K. Patel, "Pharmacophore modeling, validation, 3D virtual screening, docking, design and in silico ADMET simulation study of histone deacetylase class-I inhibitors," Medicinal Chemistry Research, vol. 23, no. 11, pp. 4853–4864, 2014.

[27] S. Hashemi, A. Shariﬁ, S. Zareei, G. Mohamedi, M. Biglar, and M. Amanlou, "Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamics studies," Research in Pharmaceutical Sciences, vol. 15, no. 3, pp. 226–240, 2020.

[28] D. Hecht and G. B. Fogel, "Computational intelligence methods for docking scores," Current Computer-Aided Drug Design, vol. 5, no. 1, pp. 56–68, 2009.

[29] M. M. Ekawati, M. A. F. Nasution, S. Siregar, I. F. Rizki, and U. S. F. Tambunan, "Pharmacophore-based virtual screening and molecular docking simulation of terpenoid compounds as the inhibitor of sonic hedgehog protein for colorectal cancer therapy," in IOP Conference Series: Materials Science and Engineering, Semarang, Indonesia, 2019.

[30] S. O. Malayeri, K. Abnous, A. Arab et al., "Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents," Bioorganic & Medicinal Chemistry, vol. 25, no. 3, pp. 1294–1302, 2017.

[31] T. Abdizadeh, M. R. Kalani, K. Abnous et al., "Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents," European Journal of Medicinal Chemistry, vol. 132, pp. 42–62, 2017.

[32] D. Ooms, R. Palm, V. Leemans, and M. F. Destain, "A sorting optimization curve with quality and yield requirements," Pattern Recognition Letters, vol. 31, no. 9, pp. 983–990, 2010.